Associate Professor of Pathology, Brigham and Women's Hospital
Medical Genetics
Dr. Jonathan A. Fletcher, MD
|
|
Give Review
Jonathan Fletcher works in the field of Medical Genetics. He graduated from Boston University School of Medicine. Boston University School of Medicine is ranked 30/52 in Research/PrimaryCare. Jonathan A. Fletcher is a published physician. He published 99 publications, including: 'Preclinical activity of selinexor, an inhibitor of XPO1, in sarcoma.' He accepts Medicare payments and is listed with Medicare.gov.
Publications
- Ponatinib Inhibits Polyclonal Drug-Resistant KIT Oncoproteins and Shows Therapeutic Potential in Heavily Pretreated Gastrointestinal Stromal Tumor (GIST) Patients.
- c-Jun promotes cell migration and drives expression of the motility factor ENPP2 in soft tissue sarcomas.
- PRC2 is recurrently inactivated through EED or SUZ12 loss in Malignant peripheral nerve sheath tumors.
- A recurrent neomorphic mutation in MYOD1 defines a clinically aggressive subset of embryonal rhabdomyosarcoma associated with PI3K-AKT pathway mutations.
- Dystrophin is a tumor suppressor in human Cancers with myogenic programs.
- Identification of aurora kinase A as an unfavorable prognostic factor and potential treatment target for metastatic gastrointestinal stromal tumors.
- Frequent expression of KIT in endometrial stromal sarcoma with YWHAE genetic rearrangement.
- VCL-ALK Renal Cell Carcinoma in Children With Sickle-cell Trait: The Eighth Sickle-cell Nephropathy?
- MED12 mutations in leiomyosarcoma and extrauterine leiomyoma.
- Genome-wide functional screening identifies CDC37 as a crucial HSP90-cofactor for KIT oncogenic expression in gastrointestinal stromal tumors.
- Anti-KIT monoclonal antibody inhibits imatinib-resistant gastrointestinal stromal tumor growth.
- Cyclin D1 as a Diagnostic Immunomarker for Endometrial Stromal Sarcoma With YWHAE-FAM22 Rearrangement.
- Protein Kinase C Inhibitor AEB071 Targets Ocular Melanoma Harboring GNAQ Mutations via Effects on the PKC/Erk1/2 and PKC/NF-κB Pathways.
- Sorafenib Inhibits Many Kinase Mutations Associated with Drug-Resistant Gastrointestinal Stromal Tumors.
- The HSP90 Inhibitor, AT13387, Is Effective against Imatinib-Sensitive and -Resistant Gastrointestinal Stromal Tumor Models.
- Efficacy and Safety of Regorafenib in Patients With Metastatic and/or Unresectable GI Stromal Tumor After Failure of Imatinib and Sunitinib: A Multicenter Phase II Trial.
- The Clinicopathologic Features of YWHAE-FAM22 Endometrial Stromal Sarcomas: A Histologically High-grade and Clinically Aggressive Tumor.
- 14-3-3 fusion oncogenes in high-grade endometrial stromal sarcoma.
- The Protein Kinase C Inhibitor Enzastaurin Exhibits Antitumor Activity against Uveal Melanoma.
- Aberrant AKT activation drives well-differentiated liposarcoma.
- Reporting of diagnostic cytogenetic results.
- ALK rearrangement in sickle cell trait-associated renal medullary carcinoma.
- Strong expression of IGF1R in pediatric gastrointestinal stromal tumors without IGF1R genomic amplification.
- Molecular and clinicopathologic characterization of gastrointestinal stromal tumors (GISTs) of small size.
- Trisomy 18 is a consistent cytogenetic feature in pilomatricoma.
- Absence of BRAF, NRAS, KRAS, HRAS mutations, and RET/PTC gene rearrangements distinguishes dominant nodules in Hashimoto thyroiditis from papillary thyroid carcinomas.
- Discovery of a small-molecule type II inhibitor of wild-type and gatekeeper mutants of BCR-ABL, PDGFRalpha, Kit, and Src kinases: novel type II inhibitor of gatekeeper...
- Carbonic anhydrase II. A novel biomarker for gastrointestinal stromal tumors.
- Proapoptotic activity of bortezomib in gastrointestinal stromal tumor cells.
- Phase II study of neoadjuvant imatinib in glioblastoma: evaluation of clinical and molecular effects of the treatment.
- Molecular target modulation, imaging, and clinical evaluation of gastrointestinal stromal tumor patients treated with sunitinib malate after imatinib failure.
- Inhibitors of deacetylases suppress oncogenic KIT signaling, acetylate HSP90, and induce apoptosis in gastrointestinal stromal tumors.
- Cytogenetics and fluorescence in situ hybridization as adjuncts to cytology in the diagnosis of Malignant mesothelioma.
- Targeting human gastrointestinal stromal tumor cells with a quadruplex-binding small molecule.
- Profiling critical Cancer gene mutations in clinical tumor samples.
- Imatinib targeting of KIT-mutant oncoprotein in melanoma.
- Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor.
- Correlation of kinase genotype and clinical outcome in the North American Intergroup Phase III Trial of imatinib mesylate for treatment of advanced gastrointestinal st...
- Osteofibrous dysplasia and adamantinoma in children and adolescents: a clinicopathologic reappraisal.
- Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stro...
- Molecular detection of PPAR gamma rearrangements and thyroid carcinoma in preoperative fine-needle aspiration biopsies.
- Pediatric KIT wild-type and platelet-derived growth factor receptor alpha-wild-type gastrointestinal stromal tumors share KIT activation but not mechanisms of genetic ...
- Clonal evolution of resistance to imatinib in patients with metastatic gastrointestinal stromal tumors.
- BRAF in papillary thyroid carcinoma of ovary (struma ovarii).
- Genomic and functional evidence for an ARID1A tumor suppressor role.
- An in vitro cytologic assay for evaluation of the KIT signaling pathway in gastrointestinal stromal tumors.
- Distinctive cytogenetic profile in benign metastasizing leiomyoma: pathogenetic implications.
- Histone H2AX is a mediator of gastrointestinal stromal tumor cell apoptosis following treatment with imatinib mesylate.
- Molecular correlates of imatinib resistance in gastrointestinal stromal tumors.
- Heat shock protein 90 inhibition in imatinib-resistant gastrointestinal stromal tumor.
- Oncogenic MITF dysregulation in clear cell sarcoma: defining the MiT family of human Cancers.
- Cytogenetic and p53 profiles in congenital cystic adenomatoid malformation: insights into its relationship with pleuropulmonary blastoma.
- Clinical and molecular studies of the effect of imatinib on advanced aggressive fibromatosis (desmoid tumor).
- Genetics of soft tissue tumors.
- Tumor suppressor genes in breast Cancer: the gatekeepers and the caretakers.
- Cytogenetic aberrations in perineurioma: variation with subtype.
- Imatinib mesylate: an attractive alternative in young children with large, surgically challenging dermatofibrosarcoma protuberans.
- Familial gastrointestinal stromal tumor syndrome: phenotypic and molecular features in a kindred.
- Molecular and clinical analysis of locally advanced dermatofibrosarcoma protuberans treated with imatinib: Imatinib Target Exploration Consortium Study B2225.
- KIT gene deletions at the intron 10-exon 11 boundary in GI stromal tumors.
- USP6 and CDH11 oncogenes identify the neoplastic cell in primary aneurysmal bone cysts and are absent in so-called secondary aneurysmal bone cysts.
- Midline carcinoma of children and young adults with NUT rearrangement.
- PKC412 inhibits the zinc finger 198-fibroblast growth factor receptor 1 fusion tyrosine kinase and is active in treatment of stem cell Myeloproliferative disorder.
- Biology of gastrointestinal stromal tumors.
- Protein Kinase C theta (PKCtheta) expression and constitutive activation in gastrointestinal stromal tumors (GISTs).
- KIT-negative gastrointestinal stromal tumors: proof of concept and therapeutic implications.
- The chimeric FUS/CREB3l2 gene is specific for low-grade fibromyxoid sarcoma.
- Overexpression, amplification, and androgen regulation of TPD52 in prostate Cancer.
- Activation of the GLI oncogene through fusion with the beta-actin gene (ACTB) in a group of distinctive pericytic Neoplasms: pericytoma with t(7;12).
- Role of KIT and platelet-derived growth factor receptors as oncoproteins.
- Targeted therapy in breast Cancer: the HER-2/neu gene and protein.
- USP6 (Tre2) fusion oncogenes in aneurysmal bone cyst.
- Cavernous sinus and leptomeningeal metastases arising from a squamous cell carcinoma of the face: case report.
- KIT mutations are common in testicular seminomas.
- Biology of gastrointestinal stromal tumors: KIT mutations and beyond.
- HER-2/neu testing in breast Cancer.
- The role of chromosomal translocation (15;19) in the carcinoma of the upper aerodigestive tract in children.
- Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor.
- Gonadotropic pituitary carcinoma: HER-2/neu expression and gene amplification. Report of two cases.
- Soft tissue sarcomas of adults: state of the translational science.
- Cloning of an Alpha-TFEB fusion in renal tumors harboring the t(6;11)(p21;q13) chromosome translocation.
- Genetic and biological subgroups of low-stage follicular thyroid Cancer.
- Inhibition of FLT3 in MLL. Validation of a therapeutic target identified by gene expression based classification.
- PDGFRA activating mutations in gastrointestinal stromal tumors.
- BRD4-NUT fusion oncogene: a novel mechanism in aggressive carcinoma.
- CHIPing soft tissue tumors: will the paradigms be changed?
- The Her-2/neu gene and protein in breast Cancer 2003: biomarker and target of therapy.
- Molecular genetic characterization of the EWS/CHN and RBP56/CHN fusion genes in extraskeletal myxoid chondrosarcoma.
- Constitutive activation of insulin receptor substrate 1 is a frequent event in human tumors: therapeutic implications.
- PPARgamma ligands inhibit primary tumor growth and metastasis by inhibiting angiogenesis.
- Prognostic value of KIT mutation type, mitotic activity, and histologic subtype in gastrointestinal stromal tumors.
- Testing for KIT (CD117) in gastrointestinal stromal tumors: another HercepTest?
- Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors.
- KIT gene mutations in gastrointestinal stromal tumors: more complex than previously recognized?
- Biology and genetic aspects of gastrointestinal stromal tumors: KIT activation and cytogenetic alterations.
- Peripheral nerve sheath tumors from patients with neurofibromatosis type 1 do not have the chromosomal translocation t(X;18).
- Chromogenic in situ hybridization and FISH in pathology.
- Preclinical activity of selinexor, an inhibitor of XPO1, in sarcoma.
Schools
Boston University School Of Medicine
University Hospital
Dana Farber Cancer Institute
Conditions Treated
- Acute Leukemia
- Anemia
- Chronic Myeloid Leukemia (CML)
- Hodgkin's Disease
- View All
Doctors Specialties
- Medical Oncology
- Oncology
- Medical Genetics
Accepted Insurances
Education
-
Boston University Medical Center -
Boston University School of Medicine
Hospital
-
Dana-Farber Cancer Institute -
Brigham and Women's Hospital
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1891713392 |
| Last Name Of The Provider | FLETCHER |
| First Name Of The Provider | JONATHAN |
| View All |
Similar Doctors
|
|
Dr. Ingrid A. Holm, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Mary M. Sandstrom, PHD |
|
|
Dr. Frederick R. Bieber, PHD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Philip W. Kantoff, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Wendy S. Garrett, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Edwin Choy, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Gerald F. Cox, MD
This Doctor is OpenDoctor Recommended.
|